Accustem Sciences (ACUT) Liabilities and Shareholders Equity (2021 - 2026)

Accustem Sciences (ACUT) has reported Liabilities and Shareholders Equity for 6 consecutive years, with $1.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity changed 0.07% year-over-year to $1.5 million; the TTM figure through Mar 2026 stood at $6.3 million (up 240.71% YoY), while the FY2025 annual figure was $1.5 million, up 2947.03% from the prior year.
• Liabilities and Shareholders Equity steadied at $1.5 million in Q1 2026 per ACUT's latest filing, from $1.5 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $3.3 million in Q1 2022 and bottomed at $50851.0 in Q4 2024.
• Historically, Liabilities and Shareholders Equity has averaged $1.0 million across 5 years, with a median of $939689.0 in 2022.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity plunged 92.39% — and 2025, when it soared 2947.03%.
• Accustem Sciences' Liabilities and Shareholders Equity stood at $939689.0 in 2022, then plunged by 85.75% to $133897.0 in 2023, then plunged by 62.02% to $50851.0 in 2024, then jumped by 2947.03% to $1.5 million in 2025, then climbed by 0.01% to $1.5 million in 2026.
• Business Quant data shows ACUT's Liabilities and Shareholders Equity at $1.5 million in Q1 2026, $1.5 million in Q4 2025, and $1.6 million in Q3 2025.